Cargando…
Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs
Long non-coding RNAs (lncRNAs) play key roles in cancer and are at the vanguard of precision therapeutic development. These efforts depend on large and high-confidence collections of cancer lncRNAs. Here, we present the Cancer LncRNA Census 2 (CLC2). With 492 cancer lncRNAs, CLC2 is 4-fold greater i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210278/ https://www.ncbi.nlm.nih.gov/pubmed/34316704 http://dx.doi.org/10.1093/narcan/zcab013 |
_version_ | 1783709277698916352 |
---|---|
author | Vancura, Adrienne Lanzós, Andrés Bosch-Guiteras, Núria Esteban, Mònica Torres Gutierrez, Alejandro H Haefliger, Simon Johnson, Rory |
author_facet | Vancura, Adrienne Lanzós, Andrés Bosch-Guiteras, Núria Esteban, Mònica Torres Gutierrez, Alejandro H Haefliger, Simon Johnson, Rory |
author_sort | Vancura, Adrienne |
collection | PubMed |
description | Long non-coding RNAs (lncRNAs) play key roles in cancer and are at the vanguard of precision therapeutic development. These efforts depend on large and high-confidence collections of cancer lncRNAs. Here, we present the Cancer LncRNA Census 2 (CLC2). With 492 cancer lncRNAs, CLC2 is 4-fold greater in size than its predecessor, without compromising on strict criteria of confident functional/genetic roles and inclusion in the GENCODE annotation scheme. This increase was enabled by leveraging high-throughput transposon insertional mutagenesis screening data, yielding 92 novel cancer lncRNAs. CLC2 makes a valuable addition to existing collections: it is amongst the largest, contains numerous unique genes (not found in other databases) and carries functional labels (oncogene/tumour suppressor). Analysis of this dataset reveals that cancer lncRNAs are impacted by germline variants, somatic mutations and changes in expression consistent with inferred disease functions. Furthermore, we show how clinical/genomic features can be used to vet prospective gene sets from high-throughput sources. The combination of size and quality makes CLC2 a foundation for precision medicine, demonstrating cancer lncRNAs’ evolutionary and clinical significance. |
format | Online Article Text |
id | pubmed-8210278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-82102782021-07-26 Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs Vancura, Adrienne Lanzós, Andrés Bosch-Guiteras, Núria Esteban, Mònica Torres Gutierrez, Alejandro H Haefliger, Simon Johnson, Rory NAR Cancer Cancer Data Resource Long non-coding RNAs (lncRNAs) play key roles in cancer and are at the vanguard of precision therapeutic development. These efforts depend on large and high-confidence collections of cancer lncRNAs. Here, we present the Cancer LncRNA Census 2 (CLC2). With 492 cancer lncRNAs, CLC2 is 4-fold greater in size than its predecessor, without compromising on strict criteria of confident functional/genetic roles and inclusion in the GENCODE annotation scheme. This increase was enabled by leveraging high-throughput transposon insertional mutagenesis screening data, yielding 92 novel cancer lncRNAs. CLC2 makes a valuable addition to existing collections: it is amongst the largest, contains numerous unique genes (not found in other databases) and carries functional labels (oncogene/tumour suppressor). Analysis of this dataset reveals that cancer lncRNAs are impacted by germline variants, somatic mutations and changes in expression consistent with inferred disease functions. Furthermore, we show how clinical/genomic features can be used to vet prospective gene sets from high-throughput sources. The combination of size and quality makes CLC2 a foundation for precision medicine, demonstrating cancer lncRNAs’ evolutionary and clinical significance. Oxford University Press 2021-04-14 /pmc/articles/PMC8210278/ /pubmed/34316704 http://dx.doi.org/10.1093/narcan/zcab013 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of NAR Cancer. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Data Resource Vancura, Adrienne Lanzós, Andrés Bosch-Guiteras, Núria Esteban, Mònica Torres Gutierrez, Alejandro H Haefliger, Simon Johnson, Rory Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs |
title | Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs |
title_full | Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs |
title_fullStr | Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs |
title_full_unstemmed | Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs |
title_short | Cancer LncRNA Census 2 (CLC2): an enhanced resource reveals clinical features of cancer lncRNAs |
title_sort | cancer lncrna census 2 (clc2): an enhanced resource reveals clinical features of cancer lncrnas |
topic | Cancer Data Resource |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210278/ https://www.ncbi.nlm.nih.gov/pubmed/34316704 http://dx.doi.org/10.1093/narcan/zcab013 |
work_keys_str_mv | AT vancuraadrienne cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas AT lanzosandres cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas AT boschguiterasnuria cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas AT estebanmonicatorres cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas AT gutierrezalejandroh cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas AT haefligersimon cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas AT johnsonrory cancerlncrnacensus2clc2anenhancedresourcerevealsclinicalfeaturesofcancerlncrnas |